Author Archives: Bruno Quinney

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

NIHR Liverpool CRF - Main Bay
#England #National Institute for Health and Care Research

Funding earmarked for research and collaboration in England 

New funding has been announced to drive research innovation and collaboration across England.  The National Institute for Health and Care Research (NIHR) has launched a funding call for new Biomedical Research Centres (BRCs), one of its flagship infrastructure schemes. The NIHR says the new… Read More

#News

European Commission
#European Commission #Measles

Marketing authorisation granted to measles therapy 

The European Commission has granted marketing authorisation to a treatment reducing the risk of measles in non-vaccinated patients.  Privigen, developed by CSL, is a human immunoglobulin therapy indicated for pre- and post-exposure prophylaxis to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended. Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Investment

Ona raises $86.6m to advance cancer-targeting ADCs 

Ona Therapeutics has announced it has raised $86.6 million to advance its first-in-class antibody-drug conjugates (ADCs) into clinical development.  The biopharmaceutical company raised the money in a Series B financing round, co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys.  Ona says the proceeds… Read More

#Business & Investment #News

Johnson & Johnson head office
#Clinical trial #Johnson & Johnson

Treatment for SLE significantly reduces disease activity 

A new treatment for systemic lupus erythematosus (SLE) could significantly reduce disease activity, results show.  Johnson & Johnson, which developed nipocalimab, says it is the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus. The blocker is designed to target and reduce pathogenic immunoglobulin… Read More

#News

FDA headquarters
#FDA #Orphan drugs #Osteosarcoma

FDA grants Orphan Drug Designation to osteosarcoma treatment 

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to a treatment for osteosarcoma.  SOT106, developed by biopharmaceutical company SOTIO Biotech, is a next-generation antibody-drug conjugate (ADC) targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumour associated stroma.  Preclinical data has shown strong anti-tumour activity… Read More

#News #Regulatory

#AI #Drug development #Sofinnova Partners

Ingenix raises €13m to scale AI drug development model 

AI company Ingenix has announced it has raised €13 million to scale its drug development model.  Ingenix says its Biological Reasoning Engine overcomes structural problems in AI drug development, integrating best-in-class models across modalities and biological scales.  The model was applied to a dual-payload ADC prioritisation… Read More

#News

#Animal models #Animal testing #European Commission

European Commission pledges to phase out animal testing 

The European Commission has said it is “firmly committed to phasing out animal testing” as it launches a roadmap for chemical safety assessments.  The latest statistics on animal use for the EU and Norway show over 9.1 million animals were used in scientific tests and experiments in the EU and Norway in 2023. This includes… Read More

#News

Alzheimer's disease drug
#Alzheimer's #FDA #Herantis Pharma #Parkinson's

Herantis to advance Alzheimer’s treatment after FDA meeting 

Herantis is set to advance the clinical development of its Alzheimer’s therapy following a positive meeting with the US Food and Drug Administration (FDA).  The company reports it completed a pre-IND meeting with the FDA to discuss the planned clinical development of HER-096, a first-in-class small peptide being developed to treat Alzheimer’s disease. … Read More

#News #Regulatory

#AI #Clinical trial #MHRA

First AI drug enters clinical development 

The first oral drug formulated by AI has been advanced into clinical development.  CRDMO Quotient Sciences has announced a Phase I study of the drug was initiated at the company’s UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA).   The study will… Read More

#News

#Assays #Clinical pharmacology #Drug discovery #Live cell analysis #Polypharmacologic

How a framework of living cells can inform drug discovery

DDW Editor Reece Armstrong speaks to Yerem Yeghiazarians, CEO and Co-Founder of Soley Therapeutics, about the limitations of current assays and how the company’s live cell approach can improve drug discovery.   RA: What are the current limitations of static assays and single endpoints in assessing how cells respond to drugs? YY: Most conventional assays provide a… Read More

#Exclusive Content

#Bacteria #Gut microbiome #Infectious diseases #Inflammatory diseases

Engineered gut bacteria could be viable alternative to FMT

An engineered gut bacteria therapy could be an alternative to foecal microbiota transplants (FMT), researchers say.  Results from a Phase Ib clinical study demonstrate comparable safety and efficacy between stool-based FMT and manufactured live biotherapeutic product (LBP).  Scientists at the Icahn School of Medicine at Mount Sinai, New York developed the… Read More

#News

Tumour microenvironment
#Cancer research #Cervical cancer #Colorectal cancer #Head and neck cancer

Drug could reduce tumours by 55%, results show 

An experimental drug could shrink tumours by up to 55%, results show.  GRWD5769, developed by biotech company Greywolf Therapeutics, is a first-in-class oral small molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), an enzyme that regulates tumour antigen presentation on MHC-I.  The drug works by… Read More

#Cancer Research #News

#AI #Assays #Drug discovery #Lab automation #STEM

How to improve lab education

Dr Tim Meyer, Research Group Leader Pharmaceutical Biotechnology at University Medical Center Göttingen, explains why the next generation of scientists must be trained differently for the lab.   Academic life science research has traditionally been optimised for novelty. Students and early-career researchers are trained to design elegant proof-of-concept experiments, execute them manually,… Read More

#Exclusive Content #Opinion

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts